The FDA has published its summary of the pivotal trial for the first bioresorbable coronary artery stent, and among the questions the agency will pose to the advisory committee at the meeting today is whether the panelists believe that more follow-up data are needed from the pivotal trial before the FDA can approve the first-of-a-kind Absorb stent. Read More
